Abstract
Lobomycosis, caused by the fungal pathogen Lacazia loboi, is a chronic deep mycosis and is only found in Central and South America. Clinically the disease is characterized by shiny keloidal nodules appearing mainly on the exposed parts such as face and the upper and lower extremities. Therapeutically the surgical removal of the lesions is considered as the only successful treatment. We describe the therapeutic response of a patient with Lobo's disease treated for one year with a combination of clofazimine (100 mg/day) and itraconazole (100 mg/day). A complete clinical and histopathological remission of the disease was observed. The patient has been followed for three years.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / therapeutic use*
-
Blastomycosis / diagnosis
-
Blastomycosis / drug therapy*
-
Clofazimine / administration & dosage
-
Clofazimine / therapeutic use*
-
Dermatomycoses / diagnosis
-
Dermatomycoses / drug therapy*
-
Drug Therapy, Combination
-
Follow-Up Studies
-
Humans
-
Itraconazole / administration & dosage
-
Itraconazole / therapeutic use*
-
Male
-
Middle Aged
-
Time Factors
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antifungal Agents
-
Itraconazole
-
Clofazimine